2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide is a synthetic molecule with the chemical formula C₁₁H₇F₃N₂O₃S. It's a complex compound that combines various functional groups, including:
* **Thiazolidine ring:** A five-membered ring containing sulfur, nitrogen, and carbon atoms.
* **Dioxo group:** Two carbonyl groups (C=O) attached to the thiazolidine ring.
* **Acetamide group:** An amide group (NHCOCH₃) attached to the thiazolidine ring.
* **Trifluorophenyl group:** A phenyl ring with three fluorine atoms attached to it.
**Importance for Research:**
This molecule's unique structure and combination of functional groups make it relevant for several areas of research, including:
* **Pharmacology and Drug Discovery:**
* **Antimicrobial activity:** Thiazolidine derivatives often exhibit antimicrobial activity against bacteria, fungi, and viruses. This compound could be a lead candidate for developing novel antibiotics or antifungal agents.
* **Anti-inflammatory activity:** Certain thiazolidine derivatives have demonstrated anti-inflammatory properties. The trifluorophenyl group might contribute to this activity by interacting with inflammatory pathways in the body.
* **Antioxidant activity:** The sulfur atom in the thiazolidine ring can act as a radical scavenger, potentially offering antioxidant properties.
* **Materials Science:**
* **Polymer chemistry:** Thiazolidine derivatives can act as monomers, building blocks for polymers with unique properties. The trifluorophenyl group could enhance the thermal and chemical stability of the polymer.
* **Analytical Chemistry:**
* **Chromatographic analysis:** The molecule's structure and properties might make it a valuable analytical standard or reagent for chromatography techniques.
**Specific Research Areas:**
There is limited publicly available information about this specific compound. However, the general structure suggests potential research applications:
* **Synthesis and Characterization:** Researchers might be interested in developing efficient synthesis methods for this compound and studying its physicochemical properties like melting point, solubility, and spectral characteristics.
* **Biological Activity Studies:** Biological assays would be necessary to determine the compound's potential antimicrobial, anti-inflammatory, or antioxidant activities.
* **Structure-Activity Relationship (SAR):** Modifying the structure of this compound, for example, by changing the substituents on the phenyl ring or the thiazolidine ring, could help identify more potent and selective analogues for specific biological targets.
**Overall:**
2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide represents a starting point for further research in various fields, particularly in drug discovery, materials science, and analytical chemistry. Further research and studies are needed to fully explore its potential applications and unlock its therapeutic or technological benefits.
ID Source | ID |
---|---|
PubMed CID | 648553 |
CHEMBL ID | 1528050 |
CHEBI ID | 121058 |
Synonym |
---|
smr000014273 |
2-(dioxo-thiazolidin-3-yl)-n-(2,3,4-trifluoro-phenyl)-acetamide |
BAS 07213796 |
MLS000075181 |
CHEBI:121058 |
AKOS000400151 |
2-(2,4-dioxo-1,3-thiazolidin-3-yl)-n-(2,3,4-trifluorophenyl)acetamide |
HMS2353F13 |
STL380763 |
CHEMBL1528050 |
2-(2,4-dioxo-3-thiazolidinyl)-n-(2,3,4-trifluorophenyl)acetamide |
Q27209296 |
sr-01000320338 |
SR-01000320338-1 |
Class | Description |
---|---|
organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 25.1189 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 39.8107 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
GLS protein | Homo sapiens (human) | Potency | 19.9526 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 24.8446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 3.9811 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |